Wolff Olins has created the new brand identity for global healthcare company GSK (formerly GlaxoSmithKline), aiming to better express its focus on innovation. The agency was brought on board around 18 ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

It stands out in a region where Amish farms and hills covered with second-growth red-oak woods, parks, and hiking trails ...

Guggenheim analyst Seamus Fernandez downgraded GSK (GSK) to Neutral from Buy without a price target following the Q3 report. While the ...

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

Questions remain about GSK’s ability to come up with new drugs and litigation over the antacid Zantac, and the stock still ...

Barclays lowered the firm’s price target on GSK (GSK) to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares.

The effort by the Center for Regenerative Medicine of Boston University, Boston Medical Center, and GSK aims to find new ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health ...

GSK launched Shingrix in China in 2020. Meanwhile, the company is also investing in additional manufacturing capacity to meet the expected demand, with a new plant due to come online in 2024.